Dynavax Technologies Corporation (0IDA.L)
USD 12.91
(-0.26%)
USD 12.91
(-0.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.66 Million USD | -92.97% |
| 2022 | 307.69 Million USD | 109.6% |
| 2021 | 95.7 Million USD | 311.88% |
| 2020 | -46.84 Million USD | 41.49% |
| 2019 | -114.09 Million USD | 23.26% |
| 2018 | -135.07 Million USD | -67.58% |
| 2017 | -90.71 Million USD | 19.39% |
| 2016 | -110.18 Million USD | -5.89% |
| 2015 | -104.85 Million USD | -15.29% |
| 2014 | -89.28 Million USD | -39.17% |
| 2013 | -65.39 Million USD | 3.61% |
| 2012 | -66.39 Million USD | -44.41% |
| 2011 | -45.03 Million USD | -26.36% |
| 2010 | -53.25 Million USD | -201.71% |
| 2009 | -12.16 Million USD | 53.3% |
| 2008 | -21.29 Million USD | 62.49% |
| 2007 | -71.09 Million USD | -27.22% |
| 2006 | -60.66 Million USD | -184.59% |
| 2005 | -19.35 Million USD | -42.47% |
| 2004 | -15.43 Million USD | 20.95% |
| 2003 | -17.18 Million USD | 4.41% |
| 2002 | -17.98 Million USD | 7.94% |
| 2001 | -19.53 Million USD | -66.68% |
| 2000 | -11.71 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 8.03 Million USD | 336.61% |
| 2024 Q1 | -14.63 Million USD | -269.05% |
| 2023 Q4 | 5.48 Million USD | -63.04% |
| 2023 Q3 | 14.83 Million USD | 100.26% |
| 2023 Q2 | 7.4 Million USD | 176.25% |
| 2023 Q1 | -9.71 Million USD | -113.95% |
| 2023 FY | - USD | -92.97% |
| 2022 FY | - USD | 109.6% |
| 2022 Q4 | 69.65 Million USD | 1.08% |
| 2022 Q1 | 34.46 Million USD | -58.5% |
| 2022 Q2 | 130.41 Million USD | 278.38% |
| 2022 Q3 | 68.91 Million USD | -47.16% |
| 2021 Q4 | 83.04 Million USD | 334.06% |
| 2021 Q1 | 32.91 Million USD | 410.92% |
| 2021 Q2 | 12.48 Million USD | -62.06% |
| 2021 Q3 | 19.13 Million USD | 53.23% |
| 2021 FY | - USD | 311.88% |
| 2020 Q4 | -10.58 Million USD | 38.28% |
| 2020 FY | - USD | 41.49% |
| 2020 Q3 | -17.15 Million USD | 11.19% |
| 2020 Q1 | -12.52 Million USD | 47.76% |
| 2020 Q2 | -19.31 Million USD | -54.17% |
| 2019 Q2 | -24.8 Million USD | 21.66% |
| 2019 FY | - USD | 23.26% |
| 2019 Q1 | -31.66 Million USD | 14.93% |
| 2019 Q3 | -24.74 Million USD | 0.24% |
| 2019 Q4 | -23.98 Million USD | 3.08% |
| 2018 Q3 | -33.11 Million USD | 1.5% |
| 2018 FY | - USD | -67.58% |
| 2018 Q4 | -37.21 Million USD | -12.38% |
| 2018 Q1 | -34.55 Million USD | -29.68% |
| 2018 Q2 | -33.62 Million USD | 2.71% |
| 2017 Q4 | -26.64 Million USD | -23.31% |
| 2017 Q2 | -20.32 Million USD | -6.41% |
| 2017 Q3 | -21.6 Million USD | -6.34% |
| 2017 Q1 | -19.09 Million USD | 1.16% |
| 2017 FY | - USD | 19.39% |
| 2016 Q4 | -19.32 Million USD | 43.52% |
| 2016 Q2 | -28.71 Million USD | -6.76% |
| 2016 Q1 | -26.89 Million USD | 0.2% |
| 2016 FY | - USD | -5.89% |
| 2016 Q3 | -34.21 Million USD | -19.16% |
| 2015 Q4 | -26.94 Million USD | 3.99% |
| 2015 Q3 | -28.06 Million USD | -21.88% |
| 2015 FY | - USD | -15.29% |
| 2015 Q2 | -23.02 Million USD | 10.17% |
| 2015 Q1 | -25.63 Million USD | -15.21% |
| 2014 Q1 | -13.5 Million USD | -7.44% |
| 2014 FY | - USD | -39.17% |
| 2014 Q2 | -24.51 Million USD | -81.56% |
| 2014 Q4 | -22.25 Million USD | 24.53% |
| 2014 Q3 | -29.48 Million USD | -20.27% |
| 2013 Q2 | -17.13 Million USD | 17.58% |
| 2013 Q4 | -12.56 Million USD | 19.71% |
| 2013 FY | - USD | 3.61% |
| 2013 Q3 | -15.65 Million USD | 8.67% |
| 2013 Q1 | -20.79 Million USD | -4.19% |
| 2012 FY | - USD | -44.41% |
| 2012 Q1 | -15.72 Million USD | -192.69% |
| 2012 Q2 | -14.71 Million USD | 6.45% |
| 2012 Q3 | -16.59 Million USD | -12.8% |
| 2012 Q4 | -19.95 Million USD | -20.26% |
| 2011 Q4 | -5.37 Million USD | 63.13% |
| 2011 Q3 | -14.57 Million USD | -46.21% |
| 2011 Q2 | -9.96 Million USD | 42.19% |
| 2011 Q1 | -17.24 Million USD | -8.05% |
| 2011 FY | - USD | -26.36% |
| 2010 Q2 | -4.31 Million USD | 51.35% |
| 2010 FY | - USD | -201.71% |
| 2010 Q4 | -15.95 Million USD | -92.16% |
| 2010 Q3 | -8.3 Million USD | -92.42% |
| 2010 Q1 | -8.87 Million USD | 19.27% |
| 2009 FY | - USD | 53.3% |
| 2009 Q1 | 5.4 Million USD | 105.79% |
| 2009 Q2 | 3.37 Million USD | -37.53% |
| 2009 Q3 | -10.07 Million USD | -398.31% |
| 2009 Q4 | -10.98 Million USD | -9.1% |
| 2008 FY | - USD | 62.49% |
| 2008 Q4 | 2.62 Million USD | 126.11% |
| 2008 Q3 | -10.05 Million USD | -80.04% |
| 2008 Q2 | -5.58 Million USD | 57.9% |
| 2008 Q1 | -13.27 Million USD | 3.61% |
| 2007 Q2 | -20.51 Million USD | -29.61% |
| 2007 Q1 | -15.82 Million USD | 27.19% |
| 2007 Q3 | -18.68 Million USD | 8.9% |
| 2007 Q4 | -13.76 Million USD | 26.34% |
| 2007 FY | - USD | -27.22% |
| 2006 Q4 | -21.74 Million USD | -54.52% |
| 2006 FY | - USD | -184.59% |
| 2006 Q1 | -8.05 Million USD | -2.31% |
| 2006 Q3 | -14.06 Million USD | -49.15% |
| 2006 Q2 | -9.43 Million USD | -17.08% |
| 2005 Q1 | 4.88 Million USD | 209.26% |
| 2005 FY | - USD | -42.47% |
| 2005 Q4 | -7.87 Million USD | 9.61% |
| 2005 Q3 | -8.71 Million USD | -15.9% |
| 2005 Q2 | -7.51 Million USD | -253.82% |
| 2004 Q4 | -4.47 Million USD | -26.36% |
| 2004 FY | - USD | 20.95% |
| 2004 Q3 | -3.54 Million USD | -107.26% |
| 2004 Q2 | -1.7 Million USD | 55.82% |
| 2004 Q1 | -3.86 Million USD | 78.38% |
| 2003 FY | - USD | 4.41% |
| 2003 Q4 | -17.88 Million USD | -77852.17% |
| 2003 Q1 | -4.71 Million USD | 0.0% |
| 2003 Q2 | 96 Thousand USD | 102.03% |
| 2003 Q3 | 23 Thousand USD | -76.04% |
| 2002 FY | - USD | 7.94% |
| 2001 FY | - USD | -66.68% |
| 2000 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 105.926% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 90.163% |
| Perrigo Company plc | 646.2 Million USD | 98.504% |
| Illumina, Inc. | -608 Million USD | 101.59% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 99.911% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 102.153% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 100.086% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 99.703% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 109.313% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 99.792% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 125.926% |
| Waters Corporation | 1.02 Billion USD | 99.054% |
| Biogen Inc. | 2.37 Billion USD | 99.593% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 111.056% |
| Evolus, Inc. | -41.81 Million USD | 123.119% |
| Adicet Bio, Inc. | -136.53 Million USD | 107.08% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 108.216% |
| bluebird bio, Inc. | -167.16 Million USD | 105.782% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 106.439% |
| FibroGen, Inc. | -261.4 Million USD | 103.698% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 99.424% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 121.752% |
| Homology Medicines, Inc. | -47.75 Million USD | 120.24% |
| Geron Corporation | -174.78 Million USD | 105.53% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 104.237% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 110.498% |
| Myriad Genetics, Inc. | -67.8 Million USD | 114.257% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 109.587% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 101.909% |
| Zoetis Inc. | 3.68 Billion USD | 99.738% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 119.113% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 99.17% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 96.885% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 99.79% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 126.789% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 104.202% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 103.634% |
| Verastem, Inc. | -83.16 Million USD | 111.623% |
| Nektar Therapeutics | -243.1 Million USD | 103.976% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 104.296% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 110.986% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 102.201% |
| OPKO Health, Inc. | -65.51 Million USD | 114.754% |
| Exelixis, Inc. | 196.6 Million USD | 95.083% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 97.677% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 91.077% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 117.336% |
| uniQure N.V. | -253.1 Million USD | 103.819% |
| Imunon, Inc. | -20.78 Million USD | 146.511% |
| Blueprint Medicines Corporation | -474.61 Million USD | 102.037% |
| Insmed Incorporated | -654.73 Million USD | 101.476% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 97.861% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 102.798% |
| TG Therapeutics, Inc. | 26.1 Million USD | 62.966% |
| Incyte Corporation | 919.42 Million USD | 98.949% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 101.913% |